This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated ki…

IgANC3GComplement-mediated Kidney Disease+2 more

~Estimated

~$10 – $8,750

ADARx Pharmaceuticals, Inc.NCT06989359

Phase 3

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy.

The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. …

C3G

~Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT04817618